DL-半胱氨酸盐酸盐一水合物

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: DL-半胱氨酸盐酸盐一水合物
• 中文别名: DL-半脱胺酸盐酸盐；DL-半胱氨酸盐酸盐,一水；DL-盐酸半胱氨酸一水；DL-盐酸半胱氨酸,一水
• 英文名称: cysteine hydrochloride monohydrate
• 英文别名: cysteine hydrochloride hydrate；DL-cysteine hydrochloride monohydrate；cysteine chlorhydrate monohydrate；2-amino-3-sulfanylpropanoic acid;hydron;chloride;hydrate
• 化学式: C₃H₇NO₂S*ClH*H₂O
• mdl: MFCD00151030
• 分子量: 175.636
• InChiKey: QIJRTFXNRTXDIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.79
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  65.3
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  DL-半胱氨酸盐酸盐一水合物 在 二硫化碳 、 sodium hydroxide 作用下， 以 水 为溶剂， 以12.2 g (21.2%)的产率得到2-硫氧代噻唑烷-4-羧酸
  参考文献：
  名称：

  Method for preparing 4-carboxythiazolidine-2-thione

  摘要：

  本发明揭示了某些噻唑啉和噻唑硫酮化合物，包括4-羧基噻唑啉-2-硫酮和3,4-四亚甲基-4H,5,6-二氢-1,3-噻唑硫酮，以及制备它们的方法。

  公开号：

  US03960881A1

文献信息

• Aldehyde derivatives and their use as calpain inhibitors
  申请人：FUJIREBIO Inc.

  公开号：EP0520336A3

  公开（公告）日：1993-04-07

  Aldehyde derivatives with a specific calpain inhibiting activity and a platelet-aggregation inhibiting effect with formula (I) or formula (II): wherein R1 represents an aromatic hydrocarbon group, a heterocyclic group, or a group of -X-R3 in which X represents O, -S(O)m- (m = 0, 1, or 2), and R3 represents an aromatic hydrocarbon group, a heterocyclic group, or an alkyl group; Z represents R4-Y- or R60-CH(R5)- in which Y represents a 3- to 7-membered nitrogen-containing saturated heterocyclic group, or a single cyclic saturated hydrocarbon group, R4 represents an alkyl group, an alkenyl group, an alkynyl group, an acyl group, a sulfonyl group, an alkoxycarbonyl group, a carbamoyl group, or a thiocarbamoyl group, R5 represents hydrogen, an alkyl group, or an aromatic hydrocarbon group, and R6 represents an acyl group, a carbamoyl group, a thiocarbamoyl group, or an alkyl group; and n is an integer of 1 to 5. wherein R7, R8, R9, and R10 are defined in the specification.

  醛衍生物具有特定的钙蛋白酶抑制活性和抑制血小板聚集作用，其化学式为（I）或化学式（II）： 其中，R1代表芳香烃基、杂环基，或-X-R3基团，其中X代表O、-S(O)m-（m = 0、1或2），R3代表芳香烃基、杂环基或烷基；Z代表R4-Y-或R60-CH(R5)-，其中Y代表3-至7-成员含氮饱和杂环基，或单环饱和碳氢基团，R4代表烷基、烯基、炔基、酰基、磺酰基、烷氧羰基、氨基甲酰基或硫代氨基甲酰基，R5代表氢、烷基或芳香烃基，R6代表酰基、氨基甲酰基、硫代氨基甲酰基或烷基；n为1至5的整数。 其中，R7、R8、R9和R10在说明书中有定义。
• Process and cosmetic compositions for the treatment of skin and scalp
  申请人：L'Oreal

  公开号：US03976781A1

  公开（公告）日：1976-08-24

  A method, composition and compounds useful in said compositions for treating the skin and scalp characterized by an excessive secretion of sebum to improve the condition thereof by reducing said excessive secretion of sebum includes topically applying to a human having skin and/or a scalp so characterized a cosmetic composition containing as an active ingredient a derivative of cysteine or cysteamine. The composition contains about 0.1-5 weight percent of said derivative and also contains as a carrier for the active ingredient, water, a mixture of water and a lower alkanol, a lower alkanol, a mixture of a lower alkanol and a cosmetic resin, a reducing agent, a neutralizing agent or a vegetable oil.

  一种用于治疗皮肤和头皮的方法、组合物和化合物，其特点是皮脂分泌过多，通过减少该过多的皮脂分泌改善其状况。包括将含有半胱氨酸或半胱胺衍生物作为活性成分的化妆品组合物局部涂抹于皮肤和/或头皮皮肤分泌过多的人体上。该组合物含有约0.1-5重量百分比的该衍生物，并且还含有作为活性成分载体的水、水和低级烷醇的混合物、低级烷醇、低级烷醇和化妆树脂的混合物、还原剂、中和剂或植物油。
• Oral treatment of seborrhea with cysteamine derivatives
  申请人：L'Oreal

  公开号：US04035492A1

  公开（公告）日：1977-07-12

  A method for treating a scalp characterized by an excessive secretion of sebum, to improve the condition thereof by reducing said excessive secretion comprising orally administering to a human being having a scalp so characterized a therapeutic composition comprising an ingestible carrier admixed with, as a non-toxic active compound, cysteine or cysteamine derivatives, the active compound is present in amounts of about 0.75-3 weight percent of the composition which is administered at a rate of about 1-5 mg/kg/day based on the weight of the human being during a period of about 15 days.

  一种治疗头皮过度分泌皮脂的方法，通过减少该过度分泌来改善头皮状况，包括口服给予头皮有过度分泌特征的人类的治疗组合物，该组合物包括与可摄入载体混合的，作为无毒活性化合物的半胱氨酸或半胱胺衍生物，活性化合物的含量约为组合物的0.75-3重量百分比，根据人类体重以每天1-5毫克/千克的速率给予，治疗期约为15天。
• 一种蒜氨酸的制备方法
  申请人：武汉远大弘元股份有限公司

  公开号：CN111285788B

  公开（公告）日：2022-10-14

  本发明公开了一种蒜氨酸的制备方法。该制备方法包括以下步骤：在微反应器中，将如式2所示的脱氧蒜氨酸和氧化剂在溶剂中进行氧化反应，得到如式1所示的蒜氨酸，所述氧化剂与所述如式2所示的脱氧蒜氨酸的摩尔比值为0.9～1.2。本发明所述蒜氨酸的制备方法中原料转化率高，最终产品纯度高，比旋度高，反应时间短，副反应少，且操作简单，后处理简单，具有较好的应用市场。
• New derivatives of cysteine
  申请人：——

  公开号：US04259508A1

  公开（公告）日：1981-03-31

  This invention relates in the free form or in salts or esters form, new N,S-diacyl-L-cysteines in which at least one of the acetylating radicals is 2-thenoyl radical and particularly N-acetyl, S-2-thenoyl cysteine and its esters. A process for manufacturing those new cysteines is claimed, as their utilization in therapeutic and cosmetological grounds.

  本发明涉及自由形式或盐或酯形式的新型N，S-二酰基-L-半胱氨酸，其中至少一个乙酰化基团是2-硝基基团，尤其是N-乙酰基，S-2-硝基半胱氨酸及其酯类。本发明还声明了制造这些新半胱氨酸的过程，并宣称它们在治疗和美容领域的应用。